ERBB2 and breast carcinoma: The aims of our study were to examine the robustness of 5 different genetic HER2 assays in a high throughput routine setting using TMA containing breast cancer tissue and to evaluate if different characteristics between the five HER2 genetic assays could affect the perfomance when using digitalization of the HER2 stained slides before manually scoring on a monitor screen.